Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis.

ABSTRACT:

Introduction

Multiple Sclerosis (MS) has a complex pathophysiology that involves genetic and environmental factors. DNA methylation (DNAm) is one epigenetic mechanism that can reversibly modulate gene expression. Cell specific DNAm changes have been associated with MS, and some MS therapies such as dimethyl fumarate can influence DNAm. Interferon Beta (IFNβ), was one of the first disease modifying therapies in multiple sclerosis (MS). However, how IFNβ reduces disease burden in MS is not fully understood and little is known about the precise effect of IFNβ treatment on methylation.

Methods

The objective of this study was to determine the changes in DNAm associated with INFβ use, using methylation arrays and statistical deconvolutions on two separate datasets (total n_tre

SUBMITTER: Xavier A 

PROVIDER: S-EPMC10266220 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature